Business news

MINSK, 18 March (BelTA) – The Belarusian pharmaceutical enterprise Belmedpreparaty has plans to boost the output of antitumor drugs in 2016, Belmedpreparaty Director General Pavel Kokhovets said during the visit of Belarusian Prime Minister Andrei Kobyakov to the enterprise on 18 March, BelTA has learned.

Andrei Kobyakov was informed about the results of the social and economic development of the company managed by the Pharmaceutical Industry Department of the Healthcare Ministry in 2015 and the prospects for 2016. After that, the official was given a tour of the unit producing antitumor drugs in the form of lyophilic powders and injectable solutions.

Pavel Kokhovets said that the investment project to upgrade the facilities producing anticancer drugs in the form of lyophilic powders and injectable solutions was completed in 2013. Today the enterprise operates cutting-edge production facilities that meet modern standards. “The facilities enable us to fully satisfy the demand of the domestic healthcare system and also export our products,” Pavel Kokhovets stressed. He noted that the investment project was unparalleled in Belarus and in the CIS.

The output capacity of the upgraded facilities is around 9.7 million units (ampoules and vials) per year. Last year, the enterprise manufactured Br400.5 billion worth of drugs. The company has plans to increase the output to Br416.3 billion worth of products.

The Belarusian pharmaceutical enterprise Belmedpreparaty produces more than twenty types of generic cancer drugs and two brand-name drugs Fotolon and Temodex. “Their efficacy has been established in a number of clinical trials conducted by the leading cancer center of Belarus, the Alexandrov Center for Oncology and Medical Radiology,” Pavel Kokhovets said.

Belmedpreparaty is the oldest and largest pharmaceutical company in Belarus. It has a multi-stage production cycle based on knowledge-intensive technologies. The company offers a wide range of medications of different pharmacotherapeutic groups. Over the past twenty years, the product lineup has expanded from 27 to 400 drugs.